富科症:对一种罕见疾病的回顾
Burcu Pekdemir1, Mikhael Bechelany2,3, Sercan Karav1
1Department of Molecular Biology and Genetics, Çanakkale Onsekiz Mart University, Çanakkale 17100, Turkey.
International journal of molecular sciences
|January 11, 2025
概括
富科症是一种罕见的遗传性疾病,源于α-L-富科酶缺乏,导致神经炎症和严重症状. 早期诊断和基因疗法等新疗法为这种具有挑战性的溶酶体储存疾病提供了希望.
科学领域:
- 生物化学 生物化学
- 遗传学 遗传学 是一个
- 神经科学是一个神经科学.
背景情况:
- 福科西多症是一种罕见的溶酶体储存疾病 (LSD),由FUCA1基因突变引起,导致α-L-fucosidase缺乏.
- 这种缺陷导致富可糖基质在 lysosomes 中积累,导致细胞功能障碍和二次存储缺陷.
- 中枢神经系统特别受到影响,溶酶体功能障碍导致神经炎症,神经元损失和渐进的神经退行.
研究的目的:
- 阐明福科症的病理生理学,重点关注神经炎症在疾病进展中的作用.
- 审查目前和新兴的治疗策略,突出挑战和潜在的突破.
- 强调早期诊断对于这种罕见的LSD的有效管理至关重要.
主要方法:
- 关于富可症病理生理学,临床表现和治疗选择的文献综述.
- 对 alfa-L-fucosidase 缺乏和基质积累背后的分子机制的分析.
- 评估当前的治疗方法,包括造血细胞移植,基因疗法和酶替代疗法.
主要成果:
- 富科症的特征是严重的神经炎症,导致智力障碍,运动缺陷 (无氧性,性) 和.
- 目前的治疗方法,如造血细胞移植,具有显著的风险和有限的疗效.
- 基因疗法由于高效的细胞集成和安全性而显示出前景,而酶替代疗法面临着血脑屏障的挑战.
结论:
- 富科症呈现出神经和运动的迅速衰退,强调了及时干预的必要性.
- 虽然目前还没有确定的治疗方法,但基因治疗和酶替代疗法是有前途的途径.
- 早期诊断对于改善fucosidosis患者的治疗结果至关重要,fucosidosis是一种罕见而毁灭性的溶酶体储存疾病.
相关概念视频
01:23Cystic Fibrosis: Pathogenesis
185
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
185
01:24Cystic Fibrosis: Management
139
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
139
01:22Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
01:35Pedigree Analysis
83.9K
Overview
83.9K
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
76
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
76
01:27Glucose Transporters
22.4K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.4K